Lipoprotein ( a ) and Atherogenic Indices in Sudanese Patients with Type 2 Diabetes

Mohieldein, Abdelmarouf; Abdalla, Khairia Eltahir; Hasan, Mohammad Mahmudul

doi:10.12816/0023976

Cited by 7 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies on Lp(a) levels in Africa have also reported elevated levels in the T2DM population. Mohieldein et al in 2014 reported that T2DM patients in Sudan had a significantly higher Lp(a) level [22]. This was similar to the finding of Ogbera and Azenabor in Nigeria [23].…”

Section: Discussionsupporting

confidence: 63%

Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients

Joseph

Ganjifrockwala

George

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Lipoprotein (a) (Lp(a)) which is a low-density lipoprotein-like particle containing apo(a) is considered as an emergent cardiovascular risk factor. Type 2 diabetes mellitus (T2DM) is associated with a two- to threefold increase in the risk of cardiovascular disease (CVD). The aim of this study was to investigate the levels of Lp(a) in Black South African T2DM patients and its association with other metabolic factors. 67 T2DM patients and 48 healthy control participants were recruited for the cross-sectional study. The Lp(a) level was determined by ELISA and the result was analyzed using SPSS. The Lp(a) level in diabetics was found to be significantly increased (P = 0.001) when compared to the normal healthy group. In the diabetic group, the Lp(a) levels correlated significantly with the duration of diabetes (P = 0.008) and oxidized LDL (ox-LDL) levels (P = 0.03) and decreased total antioxidant capacity (P = 0.001). The third tertile of Lp(a) was significantly correlated with increased ox-LDL, C-reactive protein, and triglycerides and decreased total antioxidant capacity.

show abstract

Section: Discussionsupporting

confidence: 63%

Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients

Joseph

Ganjifrockwala

George

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…This prevalence of hyperlipoproteinemia (a) in type 2 diabetics varies from one study to another and from one country to another. A Moroccan study by Idrissi et al [12] showed a prevalence of around 31.2% which is almost identical to ours while a Sudanese study by Mohieldein et al [13] presented a prevalence of 51.4% which is significantly higher than our results. These differences observed in the prevalence of hyperlipoproteinemia (a) within these different studies could be linked to the ethnic and racial variability of the populations studied, to the different dosing methods used but also and above all to the usual values taken into consideration as a threshold value for the risk of cardiovascular disease.…”

Section: Discussionsupporting

confidence: 86%

“…Our findings were confirmed by several other studies [14,15]. However, the Sudanese study by Mohieldein et al [13] showed results which contradict ours where the mean serum Lp(a) values were significantly higher in their healthy controls compared to their type 2 diabetic patients. Plasma Lp(a) concentrations are generally established by age 5 and remain constant throughout adulthood [11] but the pathophysiological mechanism by which individuals with type 2 diabetes have higher plasma levels has not been well elucidated, Hernández et al [16] believe that triglycerides and urinary albumin excretion rate are the main factors influencing serum Lp(a) levels in the diabetic population.…”

Section: Discussionsupporting

confidence: 85%

Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus

Sambou,

Diouf,

Coly

et al. 2024

IJBcRR

View full text Add to dashboard Cite

Introduction: Lipoprotein (a) is made up of an atherogenic LDL lipoparticle and a potentially thrombogenic apoprotein a and is therefore responsible for cardiovascular disease. The objective of this study is to evaluate serum lipoprotein (a) status and to investigate the correlation of elevated serum lipoprotein (a) levels with other cardiovascular risk factors in type 2 diabetics. Materials and Methods: This is a case-control study involving 82 patients, 37 type 2 diabetic patients and 45 non-diabetic control subjects. Sociodemographic data were collected and each patient underwent routine lipid assessment and lipoprotein (a) testing. Results: The prevalence of hyperlipoproteinemia (a) is 17.8% in control subjects and 29.7% in type 2 diabetics. HDL cholesterolemia is significantly higher in controls than in type 2 diabetics (p =0.028) while LDL cholesterol and serum lipoprotein (a) levels are higher in type 2 diabetics than in controls with a statistically significant difference (p=0.025 and p=0.026 respectively). The mean lipoprotein (a) values of 0.36±0.34 g/l in women are higher than those of male subjects which are 0.28±0.20 g/l (p=0.171). Mean serum lipoprotein (a) levels of 0.39±0.32 g/l in type 2 diabetics are significantly higher than those of controls which are 0.25±0.21 g/l (p= 0.026). Plasma concentrations of lipoprotein (a) vary with age and appear to be increased beyond the age of 45. There is no correlation between lipoprotein (a) and other cardiovascular risk factors. Conclusion: Hyperlipoproteinemia (a) is common in type 2 diabetics and women have the highest plasma levels. Serum lipoprotein (a) concentrations are not correlated with other cardiovascular risk factors and therefore constitute an independent risk factor.

show abstract

“…In the atherothrombotic range [8], Lp(a) levels of ≥ 75 nmol.L −1 were defined as abnormally high [24], and used to define CVD risk [12]. The prevalence of Lp(a) > 75 nmol.L −1 in our study was 31.2%, this result are in accordance with previus findings [24][25][26][27]. Heller FR, et al [25] found a prevalence about 20% in 146 patients with Diabetes Mellitus.…”

Section: Laboratory Examinationsupporting

confidence: 93%

Association between Lipoprotein (a) Concentration, Glycemic Control and Diabetes Complications in Moroccan Patients with Type 2 Diabetes Mellitus

Aboulmakarim¹,

Latifa²,

Soumia³

et al. 2023

Ann Endocrinol Metab

View full text Add to dashboard Cite

Objective:The objective of this prospective study was to investigate the relationship of the levels of Lp(a) in Moroccan patients with type 2 diabetes mellitus (T2DM) with other metabolic factors related to the severity of T2DM.Material and methods: 231 T2DM patients aged over 18-years-old were analyzed. Fasting plasma glucose, lipid profile, liver and renal tests, glycated hemoglobin test (HbA1c), and Lp(a) level were measured. Sociodemographic data, clinical characteristics and anthropometric measures were reported by the patient's endocrinologists. Our results were analyzed using SPSS software. Results:The prevalence of Lp(a) > 75 nmol.L −1 was 31.2% with a median of 105.3 nmol.L −1 (IQR 87.4-154). Compared to the group without hyper lipoprotein (a), hyper lipoprotein (a) patients were more likely to be older (median 61 years [IQR 29-83] vs. 58 years [17-85]; P = 0.014), obese or overweight (21% vs. 2%; P < 0.05 ), have a longer duration of diabetes (11 years (6-19.5) vs. 10 (6-15), P = 0.053), and have a higher prevalence of previous myocardial infarction (22.2% vs. 5%; P < 0.001). In contrast, there were no significant differences in sex ratio, nephropathy, retinopathy, lipid profiles, and glycemic control between the two groups (P > 0.05). The higher Lp(a) tertile (T3) had significantly higher BMI, Waist circumference and overall macrovascular complications P < 0.05. There was a weak positive correlation between Lp(a) with total cholesterol concentration (r = 0.137, P = 0.037), and LDL-c (r = 0.17, P < 0.01). Conclusion:we suggest measuring Lp(a) in routine evaluation in T2DM patients.

show abstract

Lipoprotein ( a ) and Atherogenic Indices in Sudanese Patients with Type 2 Diabetes

Cited by 7 publications

References 31 publications

Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients

Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients

Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus

Association between Lipoprotein (a) Concentration, Glycemic Control and Diabetes Complications in Moroccan Patients with Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About